Titlebook: Clinical Management of Acute Lymphoblastic Leukemia; From Bench to Bedsid Mark R. Litzow,Elizabeth A. Raetz Book 2022 Springer Nature Switz

有斑點(diǎn)

污點(diǎn)

https://doi.org/10.1007/BFb0074253t in determining who may derive the most benefit from HSCT, as well as the optimal timing of such an intervention. Meanwhile, advances in the development of alternative donor sources and reduced-intensity conditioning regimens have expanded its potential application.

HAVOC

Malleable

Horizon

Late Effects of Therapy of Acute Lymphoblastic Leukemiaon capture and reporting of even the most severe late effects, thus hampering meaningful comparisons of these across contemporary ALL protocols. This chapter summarizes the most prevalent late effects among ALL survivors and recent advances in mapping of these and outlines strategies for future research.

graphy

FIR

揉雜

遣返回國(guó)

Insul島

Genetic Mechanisms in T-Cell Acute Lymphoblastic LeukemiaMAPK, and PI3K signaling. In addition, aberrant expression of oncogenic transcription factors such as TAL1, LMO2, TLX1, and TLX3 and mutations in transcription factor tumor suppressors and epigenetic regulators result in altered differentiation and increased self-renewal.